Showing 1 - 6 results of 6 for search 'Kristen Hege', query time: 0.24s Refine Results
  1. 1
    CAR Talk: How Cancer-Specific CAR T Cells Can Instruct How to Build CAR T Cells to Cure HIV

    CAR Talk: How Cancer-Specific CAR T Cells Can Instruct How to Build CAR T Cells to Cure HIV by Gloria B. Kim, Kristen Hege, James L. Riley

    Published 2019-09-01
    Get full text
    Article
  2. 2
    Characterizing the exposure–response relationship of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma

    Characterizing the exposure–response relationship of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma by Jamie N. Connarn, Han Witjes, Marielle van Zutphen‐van Geffen, Rik deGreef, Timothy B. Campbell, Kristen Hege, Simon Zhou, Manisha Lamba

    Published 2023-11-01
    Get full text
    Article
  3. 3
    A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms.

    A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms. by Edward Wolin, Alain Mita, Amit Mahipal, Tim Meyer, Johanna Bendell, John Nemunaitis, Pam N Munster, Luis Paz-Ares, Ellen H Filvaroff, Shaoyi Li, Kristen Hege, Hans de Haan, Monica Mita

    Published 2019-01-01
    Get full text
    Article
  4. 4
    S193: BMS-986393 (CC-95266), A G PROTEIN–COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D (GPRC5D)–TARGETED CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM A PHASE 1 STUDY

    S193: BMS-986393 (CC-95266), A G PROTEIN–COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D (GPRC5D)–TARGETED CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FRO... by Susan Bal, Jesus Berdeja, Myo Htut, Mehmet Kocoglu, Tara Gregory, Larry D. Anderson, Adriana Rossi, Daniel Egan, Luciano Costa, Lisa Kelly, Safiyyah Ziyad, Hongxiang Hu, Yanping Chen, Allison J. Kaeding, Michael Burgess, Kristen Hege, Omar Nadeem

    Published 2023-08-01
    Get full text
    Article
  5. 5
    Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma

    Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma by Mehmet Kemal Samur, Mariateresa Fulciniti, Anil Aktas Samur, Abdul Hamid Bazarbachi, Yu-Tzu Tai, Rao Prabhala, Alejandro Alonso, Adam S. Sperling, Timothy Campbell, Fabio Petrocca, Kristen Hege, Shari Kaiser, Hervé Avet Loiseau, Kenneth C. Anderson, Nikhil C. Munshi

    Published 2021-02-01
    Get full text
    Article
  6. 6
    Phase Ib study of combinations of avadomide (CC‐122), CC‐223, CC‐292, and rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma

    Phase Ib study of combinations of avadomide (CC‐122), CC‐223, CC‐292, and rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma by Vincent Ribrag, Julio C. Chavez, Carola Boccomini, Jason Kaplan, Jason C. Chandler, Armando Santoro, Paolo Corradini, Ian W. Flinn, Ranjana Advani, Philippe A. Cassier, Randeep Sangha, Vaishalee P. Kenkre, Iris Isufi, Shailaja Uttamsingh, Patrick R. Hagner, Anita K. Gandhi, Frank Shen, Sophie Michelliza, Harald Haeske, Kristen Hege, Michael Pourdehnad, John Kuruvilla

    Published 2022-02-01
    Get full text
    Article

Search Tools: